CytomX Therapeutics Profile

18.07
USD 0.77  4.09%
0%
20%

Exercise or conversion by Debanjan Ray of 3000 shares of CytomX Therapeutics subject to Rule 16b-3

CytomX Therapeutics insider trading alert for exercise of stock option (right to buy) by Debanjan Ray, Chief Financial Officer, on September 6, 2018. This event was filed by Cytomx Therapeutics Inc with SEC on 2018-09-06. Statement of changes in beneficial ownership - SEC Form 4. Debanjan Ray is currently serves as cfo, principal financial and accounting officer of CytomX Therapeutics [view details]   

CytomX Therapeutics Summary

CytomX Therapeutics (CTMX) is traded on BATS Exchange in USA. It is located in CALIFORNIA U.S.A and employs 92 people. CytomX Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.The company currently falls under 'Small-Cap' category with current market capitalization of 899.72 M. CytomX Therapeutics conducts business under Healthcare sector and is part of Biotechnology industry. This company has 44.96 M outstanding shares of which 2.41 M shares are currently shorted by private and institutional investors with about 5.45 trading days to cover. CytomX Therapeutics currently holds about 335.15 M in cash with (24.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.45.
Check CytomX Therapeutics Probability Of Bankruptcy

Ownership Allocation (%)

CytomX Therapeutics Target Price Odds Analysis

Odds Below 18.07HorizonTargetOdds Above 18.07
9.27%30 days 18.07 90.67%
Based on normal probability distribution, the odds of CytomX Therapeutics to move above current price in 30 days from now is about 90.67% (This CytomX Therapeutics probability density function shows the probability of CytomX Therapeutics Stock to fall within a particular range of prices over 30 days) .

CytomX Therapeutics Top Holders

CytomX Therapeutics Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Fmr LlcCommon Shares5.8 M133.6 M
Price T Rowe Associates IncCommon Shares3.2 M74.3 M
View CytomX Therapeutics Diagnostics

CytomX Therapeutics Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

CytomX Therapeutics Key Fundamentals

CytomX Therapeutics Against Markets

CytomX Therapeutics Current Ratings

CytomX Therapeutics 30 Days Performance Scores

Risk Adjusted
Performance Score (0 to 100)
0 
Chance of
Financial Distress (0 to 100%)
51 
Equity ratings for CytomX Therapeutics are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California. CytomX Therapeutics operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 92 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
CytomX Therapeutics SEC Filings
CytomX Therapeutics SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameCytomX Therapeutics
President CEO, DirectorSean McCarthyView All
Thematic Classification
Currently Active Investing Idea
Cancer Fighters
  Cancer Fighters
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
RegionNorth America
LocationCALIFORNIA U.S.A
Business Address151 Oyster Point Boulevard
ExchangeBATS Exchange
CIK Number0001501989
CUSIP232996751
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.cytomx.com
Phone650 515 3185
CurrencyUSD - US Dollar
Next Fiscal Year EndDecember 31, 2019
Most Recent QuarterJune 30, 2018
Last Fiscal Year EndDecember 31, 2017
Date Short InterestAugust 15, 2018

CytomX Therapeutics Directors

CytomX Therapeutics Corporate Directors

Matthew Young Independent Director
Marion McCourt Director
Charles Fuchs Director
Check also Trending Equities. Please also try Analyst Recommendations module to analyst recommendations and target price estimates broken down by several categories.
Search macroaxis.com